EVOLVE GBL HEALTHCARE ENHNCD YLD FD HEDGED UNITS
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 59
- Market Cap
- $141.7M
- Website
- http://www.atyrpharma.com
Clinical Trials
22
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- Conditions
- Interstitial Lung Disease
- Interventions
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- aTyr Pharma, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05892614
- Locations
- 🇺🇸
aTyr Investigative Site, Richmond, Virginia, United States
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- aTyr Pharma, Inc.
- Target Recruit Count
- 268
- Registration Number
- NCT05415137
- Locations
- 🇬🇧
aTyr Investigative Site, London, United Kingdom
🇯🇵Kyorin Investigative Site, Tokyo, Japan
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
- Conditions
- SARS-CoV-2 (COVID-19) Severe Pneumonia
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- aTyr Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04412668
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸aTyr Investigative Site, Toledo, Ohio, United States
🇺🇸University of Miami, Miami, Florida, United States
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
- Conditions
- Pulmonary Sarcoidosis
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- aTyr Pharma, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03824392
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸aTyr Investigative Site, Chicago, Illinois, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)
- Conditions
- Limb Girdle Muscular DystrophyFacioscapulohumeral Muscular Dystrophy
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- aTyr Pharma, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02836418
- Locations
- 🇺🇸
University of California, Irvine, ALS and Neuromuscular Center, Irvine, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
- Prev
- 1
- 2
- Next